Document Detail

Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
MedLine Citation:
PMID:  21050058     Owner:  NLM     Status:  MEDLINE    
Denosumab is a fully human monoclonal antibody with high affinity and specificity for human receptor activator of nuclear factor kappa B ligand (RANKL), the principal regulator of osteoclastic bone resorption. By binding to RANKL, denosumab prevents it from binding to its receptor on the cell surface of pre-osteoclasts and mature osteoclasts, thereby reducing the formation, activity, and survival of osteoclasts and inhibiting osteoclastic bone resorption. In a large, randomized, placebo-controlled clinical trial in postmenopausal women with osteoporosis, denosumab 60 mg administered subcutaneously every 6 months reduced levels of bone turnover markers, increased bone mineral density, and reduced the risk of vertebral fractures, hip fractures, and non-vertebral fractures. There was no significant difference between denosumab and placebo in the overall risk of adverse events or serious adverse events. Denosumab was associated with a significant increase in the risk of eczema and cellulitis, and a significant decrease in the risk of falling and concussions. Denosumab recently received regulatory approval for the treatment of postmenopausal women with osteoporosis at high risk for fracture, with no dose adjustment in patients with renal impairment. Denosumab is a new therapeutic option to reduce fracture risk in women with postmenopausal osteoporosis, especially for those with impaired renal function or with intolerance or poor response to oral therapy.
E Michael Lewiecki
Related Documents :
2192868 - Effects of thyroid hormones on bone and mineral metabolism.
12352908 - Bone mineral density and fracture prevalence in long-term kidney graft recipients.
25275978 - Return to sport after hip arthroscopy: aggregate recommendations from high-volume hip a...
15977918 - Treatment of postmenopausal osteoporosis.
12019458 - The degree of mineralization of bone tissue measured by computerized quantitative conta...
19583538 - Resurfacing versus conventional total hip arthroplasty - review of comparative clinical...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-11-04
Journal Detail:
Title:  Current medical research and opinion     Volume:  26     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-16     Completed Date:  2011-03-01     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  2807-12     Citation Subset:  IM    
New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM 87106, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Antibodies, Monoclonal, Humanized
Bone Density Conservation Agents / adverse effects,  therapeutic use*
Clinical Trials as Topic
Middle Aged
Osteoporosis, Postmenopausal / drug therapy*
RANK Ligand / adverse effects,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Bone Density Conservation Agents; 0/RANK Ligand; 4EQZ6YO2HI/denosumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cost-effectiveness of early compared to late inhaled nitric oxide therapy in near-term infants.
Next Document:  Chronic gout: epidemiology, disease progression, treatment and disease burden.